MCKESSON CORP News
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
see moreMCKESSON CORP Market News
5d
McKesson Boosts Yield; CMS OKs Clinical Registry
- McKesson announced a $0.82 quarterly dividend and received CMS designation for its Practice Insights platform as a Qualified Clinical Data Registry. Together these concrete developments strengthen McKesson’s income profile and health‑IT positioning, with potential near‑term support for MCK stock.
19d
McKesson Hits Records on Strong Specialty Sales Q3
McKesson (MCK) reached consecutive 52-week highs after reporting robust fiscal Q3 results driven by specialty and oncology growth, rising GLP‑1 distribution, and strategic portfolio moves including the Medical‑Surgical separation and exit from Europe. Operational efficiencies, prescription technology momentum, and expanded oncology networks underpin the breakout.
26d
McKesson Raises FY26 Guidance After Strong Q3 Beat
McKesson reported a powerful Q3 FY2026 with $106.2B revenue, raised adjusted EPS guidance to $38.80–$39.20, completed its Norwegian exit, and maintained dividends—moves that sharpen its North America focus and bolster investor confidence amid increasing specialty logistics competition.
17 Feb at 14:14
McKesson Q3 Beat Fuels Oncology & AI Upside —MCK!!
McKesson reported a Q3 earnings beat and raised full-year EPS guidance, driven by strong oncology and North American pharmaceuticals performance, progress toward the Medical‑Surgical spin‑off, and continued investments in automation and health IT. These concrete developments accelerated investor interest while GLP‑1 volume dynamics and regulatory exposure remain key risks.
10 Feb at 14:14
McKesson Rally: Q3 Beat, Guidance Lift Sparks Now!
McKesson (MCK) jumped after a Feb. 4 Q3 beat, raised fiscal-year guidance, and announced strategic exits and a dividend. Technical momentum (RS Rating surge) and strong peer results supported the move—investors should watch for pullbacks to support levels and monitor cash flow and margin trends.